Chargement en cours...
Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C
Treatment of hepatitis C virus (HCV) infection with ledipasvir/sofosbuvir promises tremendous benefits, but high cost may impede implementation of this regimen. Subgroups with excellent response to 8 weeks of treatment might respond to a shorter course. In ION-3, 423 previously untreated HCV genotyp...
Enregistré dans:
| Publié dans: | Open Forum Infect Dis |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4324232/ https://ncbi.nlm.nih.gov/pubmed/25734178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofu110 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|